Skip to main content

Investigational New Drugs

Ausgabe 6/2005

Special Issue: Recent Advances in Pharmacogenetic Approaches to Cancer Chemotherapy

Inhalt (14 Artikel)

The thiopurines: An update

Sally Coulthard, Linda Hogarth

A Phase I Clinical and Pharmacokinetic Study of Fenretinide Combined with Paclitaxel and Cisplatin for Refractory Solid Tumors

G. A. Otterson, J. Lavelle, M. A. Villalona-Calero, M. Shah, X. Wei, K. K Chan, B. Fischer, M. Grever

Randomized phase II trial of different schedules of administration of rebeccamycin analogue as second line therapy in non-small cell lung cancer

Afshin Dowlati, Robert Chapman, Shanmuga Subbiah, Pingfu Fu, Anne Ness, Tania Cortas, Lauren Patrick, Sherrie Reynolds, Natalie Xu, Nathan Levitan, Percy Ivy, Scot C. Remick

Phase II Study of Perifosine in Previously Untreated Patients with Metastatic Melanoma

D Scott Ernst, Elizabeth Eisenhauer, Nancy Wainman, Mary Davis, Reinhard Lohmann, Tara Baetz, Karl Belanger, Michael Smylie

Phase II study of the efficacy and safety of oral GD0039 in patients with locally advanced or metastatic renal cell carcinoma

Philip E. Shaheen, Walter Stadler, Paul Elson, Jennifer Knox, Eric Winquist, Ronald M. Bukowski

A Phase II study of celecoxib, gemcitabine, and cisplatin in advanced pancreatic cancer

Basil F. El-Rayes, Mark M. Zalupski, Anthony F. Shields, Ann Marie Ferris, Ulka Vaishampayan, Lance K. Heilbrun, Raghu Venkatramanamoorthy, Volkan Adsay, Philip A. Philip

Phase II Trial of SarCNU in Malignant Glioma: Unexpected Pulmonary Toxicity with a Novel Nitrosourea

Marc Webster, Gregory Cairncross, Stan Gertler, James Perry, Nancy Wainman, Elizabeth Eisenhauer

Activity of carboplatin in patients with advanced non-small cell lung cancer pre-treated with a non-platinum combination

Emilio Esteban-Gonzalez, Yolanda Fernández, Noemí Villanueva, Joaquin Fra, Isabel Muñiz, Isabel Palacio, Jose M. Vieitez, Esther Uña, Beatriz Mareque, Angel J. Lacave

Erratum

Erratum

Tsavaris

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.